Sympathetic modulation of lipolysis in subcutaneous adipose tissue: effects of gender and energy restriction.
To investigate the differences in the regulation of lipolysis between male and female obese subjects in vivo, we used an in situ microdialysis technique before and after 3 weeks of energy restriction. Using this method, we examined glycerol, glucose, and lactate responses after 5 minutes of epinephrine stimulation in the adipose tissues. Glycerol releases after the perfusion of phentolamine, orciprenaline, and propranolol were also studied. Sixteen subjects were studied (8 men, 8 women, 35 to 45 years of age, body mass index 38 to 50 kg/m2). In women, epinephrine provoked a greater glycerol release than in men in both abdominal and femoral regions (P < .05). In men and women there was a significant decrease in the concentration of glucose and a significant increase in lactate concentration after epinephrine stimulation (P < .001). After 3 weeks of energy restriction, glycerol release after epinephrine stimulation was greater in both sexes than that observed before energy restriction (P < .05). Both phentolamine and orciprenaline stimulated the release of glycerol (P < .01); phentolamine had a higher effect in women, while propranolol had no effect on glycerol release in both sexes. In summary, we have demonstrated that epinephrine provoked a greater lipolytic response in obese women in both abdominal and femoral adipose tissues. The lipolytic response was further enhanced after 3 weeks of energy restriction in each gender. The decrease in glucose concentration suggests that glucose may be reutilized for synthesis into new triacylglycerol. Knowledge about the sensitivity to lipolytic agents in subcutaneous adipose tissue may provide potential new approaches for modulating the lipolytic responses of subcutaneous adipose tissue differently in men and women.
Flechtner-Mors
M
M
Department of Medicine, University of Ulm, Germany.
Ditschuneit
H H
HH
Yip
I
I
Adler
G
G
D000005:Abdomen; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism*; D018663:Adrenergic Agents / Q000494:pharmacology; D000328:Adult; D002149:Energy Intake; D004837:Epinephrine / Q000008:administration & dosage; D005260:Female; D005990:Glycerol / Q000378:metabolism; D006801:Humans; D008066:Lipolysis; D008297:Male; D009921:Metaproterenol / Q000008:administration & dosage; D008875:Middle Aged; D009765:Obesity / Q000378:metabolism / Q000503:physiopathology*; D010646:Phentolamine / Q000008:administration & dosage; D011433:Propranolol / Q000008:administration & dosage; D012737:Sex Factors; D013564:Sympathetic Nervous System / Q000378:metabolism / Q000503:physiopathology*; D013848:Thigh
D018663:Adrenergic Agents; D009921:Metaproterenol; D011433:Propranolol; D005990:Glycerol; D004837:Epinephrine; D010646:Phentolamine